Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors Associated With Retinal Nerve Fiber Layer Asymmetry in Primary Open-Angle Glaucoma Among Individuals of African Ancestry.

Journal of glaucoma·2026
Same author

Statin Use and Primary Open-Angle Glaucoma Severity in Patients of African Ancestry.

Research square·2026
Same author

Partnering to Improve Pickleball Ocular Safety Awareness.

JAMA ophthalmology·2026
Same author

Risk of Ocular Hypertension With Intravitreal Triamcinolone Compared to the Dexamethasone Implant.

Journal of vitreoretinal diseases·2026
Same author

Investigating therapeutic response to netarsudil in glaucoma subjects with the <i>ARHGEF12</i> risk variant.

Frontiers in pharmacology·2026
Same author

Epidemiology of retinal disease.

Handbook of clinical neurology·2026

Related Experiment Video

Updated: May 9, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis.

Anthony J Cordisco1, Fangming Jin2, Ali G Hamedani3

  • 1From the Department of Neurology (A.J.C. and A.G.H.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

American Journal of Ophthalmology
|May 7, 2026
PubMed
Summary

Certain disease-modifying therapies (DMTs) for multiple sclerosis (MS) may reduce the risk of non-infectious uveitis (NIU). Nucleic acid synthesis inhibitors/S1P modulators showed the greatest protective effect in this study.

More Related Videos

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Related Experiment Videos

Last Updated: May 9, 2026

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Area of Science:

  • Neurology
  • Ophthalmology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system.
  • An increased risk of non-infectious uveitis (NIU) is observed in MS patients.
  • The impact of disease-modifying therapies (DMTs) on NIU risk in MS is not well understood.

Purpose of the Study:

  • To investigate the comparative risk of developing NIU among patients with MS initiating different DMTs.
  • To identify specific DMT classes associated with altered NIU risk.

Main Methods:

  • Retrospective cohort study utilizing a large US claims database (2000-2022).
  • Included adults with MS and at least two years of prior enrollment, initiating DMTs.
  • Compared risks of NIU across various DMTs (interferons, fumarates, S1P modulators, natalizumab, anti-CD20) versus glatiramer acetate using Cox models and propensity score weighting.

Main Results:

  • Nucleic acid synthesis inhibitors/S1P modulators were associated with a significantly lower risk of NIU (aHR 0.14).
  • Fumarates, anti-CD20, and interferons also showed a reduced risk of NIU compared to glatiramer acetate.
  • Natalizumab did not demonstrate a significant difference in NIU risk.

Conclusions:

  • Specific classes of DMTs, particularly nucleic acid synthesis inhibitors/S1P modulators, appear to have a protective effect against NIU in MS patients.
  • These findings suggest potential for personalized MS treatment strategies.
  • Further research may explore repurposing these DMTs for NIU treatment in broader patient populations.